Centene Corporation (CNC) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup favors a beat on adjusted EPS, with the biggest swing factor being how much of the Marketplace risk adjustment receivable management chooses to recognize in Q2 guidance — the June Wakely data (received post-Q1 earnings) is the single most important catalyst for whether the stock moves higher or lower on the print.

Heading into Q2 2026, the bar for CNC looks achievable: consensus sits at ~$0.95 adjusted EPS (current VA consensus $1.13, reflecting post-Q1 raise), and management’s own seasonality guidance called for a “step down from Q1, still profitable” quarter. The Q1 2026 print was a substantial beat — $3.37 actual vs. $2.23 consensus — and management raised full-year adjusted EPS guidance to “greater than $3.40” from “greater than $3.00,” embedding a conservative ~3% Marketplace pre-tax margin (vs. original ~4% target) pending the June Wakely data. Estimate revisions have been broadly stable-to-slightly-lower since the Q1 raise, with Q2 consensus drifting from ~$1.12 in early May to ~$1.13 today, suggesting the Street has not yet fully priced in the potential Marketplace risk adjustment upside that management flagged. The stock has rallied ~47% since the Q1 earnings date (April 28), trading at ~15.6x NTM P/E vs. a historical discount, meaning some recovery is priced in but the multiple remains well below pre-2025 levels. The key wildcard is the June Wakely claims and risk score data: if management confirms a meaningful risk adjustment receivable for the higher-acuity Silver tier membership, the full-year EPS guidance could be raised again toward or above the original ~4% Marketplace margin target, which would be a material positive surprise; conversely, any deterioration in Medicaid HBR beyond the expected seasonal step-up in Q2/Q3 would be the primary downside risk.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a moderate bar heading into Q2 — the Street models a seasonal step-down in EPS from Q1’s $3.37 to ~$1.13, consistent with management’s own guidance. The bigger swing factor is the consolidated HBR (Medical Loss Ratio), where Medicaid is expected to be seasonally elevated in Q2/Q3 and Marketplace risk adjustment recognition could move the needle materially in either direction.

Table 1 — Current Quarter Snapshot (Q2 2026 Key KPIs)

Sources: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 27, 2026. Q1 2026 actuals and Q2 2025 actuals from Visible Alpha reported figures. FY 2026 guidance from Q1 2026 earnings call (April 28, 2026).

Table 2 — Beat/Miss History (Last 8 Quarters — Top 2 KPIs: Adjusted EPS & HBR)

Source: Visible Alpha Consensus and Actuals Data. Pattern: CNC has beaten adjusted EPS consensus in 6 of the last 8 quarters, with the two misses concentrated in Q2 2025 (the trough of the Medicaid HBR deterioration cycle). HBR beats are less consistent — the company has beaten on HBR in 5 of 8 quarters, with misses typically in seasonally elevated Q2/Q3 periods. The Q1 2026 beat magnitude (+51% on EPS) was exceptional and driven by a combination of flu season favorability, weather-related utilization benefit, and genuine fundamental outperformance.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised full-year adjusted EPS guidance meaningfully at Q1 earnings (April 28) but embedded a deliberately conservative Marketplace margin assumption (~3% vs. original ~4%) pending June Wakely data. No post-earnings guidance revisions have been issued since April 28. Tone has shifted from cautious/corrective to increasingly confident, with the primary remaining uncertainty being the magnitude of the Marketplace risk adjustment receivable.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY 2026 have been remarkably stable since the Q1 earnings raise — Q2 EPS consensus has drifted only ~-1% from the post-print baseline, and FY EPS is essentially flat. This stability suggests the Street is waiting for the Q2 print and June Wakely data before making further revisions, rather than pre-positioning for upside or downside. The gap between FY consensus ($3.52) and guidance floor (>$3.40) represents modest cushion, not a stretched bar.

Source: Visible Alpha Consensus and Actuals Data. Estimate baseline (May 5, 2026) represents consensus approximately 5 trading days after the Q1 2026 earnings release (April 28, 2026). The near-zero revision in both Q2 and FY estimates since the post-print baseline reflects a Street in “wait and see” mode ahead of the June Wakely data and Q2 print. The key question is whether management will use the Q2 call to raise FY guidance again — the Marketplace risk adjustment receivable is the primary lever.

5. Stock Performance

Key Takeaway: CNC has dramatically outperformed both XLV and the S&P 500 since the Q1 2026 earnings date (April 28), driven almost entirely by multiple re-rating and sentiment recovery following the substantial Q1 beat and guidance raise. The stock is up ~47% since April 28 vs. XLV +14% and SPY +3%, with the bulk of the move occurring in the first two weeks post-earnings. The recent pullback from the ~$68–69 range to ~$64 suggests some profit-taking ahead of the print, but the stock remains well above pre-Q1 levels.

CNC vs. XLV (Health Care Select Sector ETF) vs. S&P 500 (SPY) — Indexed to 100 at April 28, 2026 (Q1 2026 Earnings Date). Source: Yahoo Finance / Stock Price Data.

Key observations: (1) CNC surged ~14% on April 28 (earnings day) and continued rallying through mid-June, peaking near $68–69. (2) XLV was broadly flat-to-modestly-positive over the same period, confirming CNC’s outperformance was company-specific rather than sector-driven. (3) The S&P 500 was essentially flat over the period, further isolating CNC’s move as driven by fundamental re-rating. (4) CNC has pulled back ~6–7% from its recent peak, consistent with pre-earnings profit-taking. The 12-month NTM P/E has expanded from ~7.2x to ~15.6x, with the 3-month move (+53%) driven roughly equally by multiple expansion (+14%) and estimate revisions. Sector ETF used: XLV (Health Care Select Sector SPDR Fund), which is appropriate for CNC’s managed care / health insurance sub-sector.

6. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Peer Q2 2026 earnings (UNH, ELV, MOH — all reported July 15–23) provide a broadly mixed-to-positive read-through for CNC. The most important signals are: (1) Medicaid cost trends are stabilizing (not accelerating), with the acuity shift from redeterminations largely behind the market; (2) state rate updates are coming in at or above expectations; (3) Marketplace/ACA performance is diverging sharply by company — MOH had a significant adverse selection problem in its shrinking book, while ELV and UNH saw better-than-expected ACA results; and (4) Medicare duals are performing well across the board. CNC’s larger scale and more aggressive Marketplace repricing strategy position it differently from MOH.

Note: All commentary below is sourced exclusively from Q2 2026 earnings calls and releases (July 2026), reflecting current-quarter (Q2 2026) results and forward outlook. No prior-quarter commentary is included.

6A. UnitedHealth Group (UNH) — Q2 2026 Earnings (Reported July 16, 2026)

6B. Elevance Health (ELV) — Q2 2026 Earnings (Reported July 15, 2026)

6C. Molina Healthcare (MOH) — Q2 2026 Earnings (Reported July 22–23, 2026)

6D. HCA Healthcare (HCA) — Q2 2026 Pre-Announcement (July 14, 2026) — Hospital Read-Through

HCA pre-announced Q2 2026 results on July 14, 2026, cutting full-year guidance due to a negative payer mix shift driven by an increase in uninsured volume from patients who lost ACA exchange coverage. HCA revised its 2026 estimate for health insurance exchange unfavorable impacts to $1.0–1.2B (from prior $600–900M). This is a negative read-through for CNC’s Marketplace segment: HCA’s data confirms that ACA subsidy expiration is driving meaningful membership loss and payer mix deterioration at hospitals, which is consistent with CNC’s own Marketplace membership attrition guidance (ending 2026 at just over 3M members from ~3.6M at Q1 end). However, CNC’s Marketplace business is on the insurer side — the uninsured volume that hurts HCA represents members who left the market entirely, which is consistent with CNC’s expected attrition and does not necessarily worsen CNC’s risk pool (healthier members are more likely to drop coverage). The HCA data is more negative for hospital operators than for managed care companies with disciplined repricing strategies like CNC.

6E. Peer Read-Through Summary

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the receipt of the June Wakely data (claims and risk score data across the ACA market), which management flagged as the key catalyst for potentially raising Marketplace margin guidance from ~3% toward the original ~4% target. No public disclosure of the June Wakely data has been made, but management will almost certainly address it on the Q2 call. Secondary developments include a new board appointment and the Nebraska work requirement launch.

• June Wakely Data (Received ~June 2026, not publicly disclosed): Management explicitly flagged on the Q1 call that the June Wakely claims and risk score data would be "key to allowing us to further refine" the Marketplace risk adjustment assumption. The current guidance embeds a conservative ~3% Marketplace pre-tax margin; if the June data confirms the higher-acuity Silver tier receivable, management could raise this to ~4% or above, implying meaningful FY EPS upside. This is the single most important item for the Q2 print. Implication: Positive if confirmed; the range management described "wraps around the original 4% target and frankly higher at the top end."
• Nebraska Medicaid Work Requirements Launch (Effective July 1, 2026): Nebraska became the first state to implement Medicaid work requirements under the One Big Beautiful Bill Act, effective July 1, 2026. CNC operates in Nebraska and management has described this as an instructive real-world test case. MOH’s Q2 commentary confirmed the rollout is gradual, with the two key implementation issues being eligibility verification methodology and the definition of medical frailty. Implication: Neutral-to-positive; early data from Nebraska will inform CNC’s 2027 planning assumptions and state rate negotiations.
• Board Appointment — Lauren Tyler (Effective June 19, 2026; Disclosed June 22, 2026): CNC appointed Lauren M. Tyler to its Board of Directors, effective June 19, 2026 (disclosed via 8-K on June 22, 2026). Tyler brings 30+ years of financial and human capital leadership experience, including senior roles at JPMorgan Chase. She will serve on the Audit Committee and Compensation and Talent Committee. CEO Sarah London noted Tyler’s "track record guiding global, complex organizations through transformation." Implication: Governance positive; no direct earnings impact. Note: effective date (June 19) precedes disclosure date (June 22).
• UNH Q2 2026 Beat and Guidance Raise (July 16, 2026): UNH reported Q2 adjusted EPS of $6.38 vs. consensus $4.89 and raised FY guidance to $19.50–$20.00 from prior floor of >$18.25. The stock rose ~8%. UNH’s strong print and guidance raise lifted managed care sentiment broadly and contributed to CNC’s stock performance in mid-July. Implication: Positive sector read-through; confirms managed care cost trends are improving.
• ELV Q2 2026 Results and CEO Stock Purchase (July 15–17, 2026): ELV reported Q2 EPS of $7.45 vs. consensus $6.18 but raised FY guidance by less than the beat, causing the stock to fall ~8.8%. Notably, CEO Gail Boudreaux purchased 2,725 shares (~$1M) on July 17 at $366–$369/share following the post-earnings selloff — a strong insider confidence signal. Implication: Mixed for CNC; ELV’s beat confirms sector improvement, but the market’s negative reaction to a “small beat and raise” is a reminder that CNC’s bar is also elevated after the Q1 rally.
• MOH Q2 2026 Marketplace Guidance Cut (July 22–23, 2026): MOH cut full-year Marketplace EPS guidance by $1.50/share due to adverse selection and non-risk-adjustable costs in its shrinking ACA book. The stock fell on the news. Implication: Negative headline read-through for CNC Marketplace, but CNC’s situation is fundamentally different (larger, growing book with deliberate repricing vs. MOH’s shrinking book).
• HCA Healthcare Guidance Cut (July 14, 2026): HCA pre-announced Q2 results and cut FY guidance, citing a $1.0–1.2B unfavorable impact from ACA subsidy expiration (vs. prior $600–900M estimate). The stock fell ~9–10%. Implication: Confirms ACA subsidy expiration is having a real impact on the healthcare system, consistent with CNC’s own Marketplace membership attrition guidance.
• CVS Health / Caremark FTC Settlement (July 14, 2026): CVS’s Caremark finalized a settlement with the FTC agreeing to curb rebate use and count TrumpRx purchases toward deductibles. Implication: Indirect; PBM reform could affect specialty drug cost dynamics for managed care companies including CNC.
• CMS Bridge Program for GLP-1 Access (Announced ~Q2 2026): CMS launched a Bridge pilot program providing Medicare patients access to GLP-1 obesity drugs at $50/month copay. CNC management expressed support on the Q1 call. Implication: Modest positive for CNC’s Medicare segment member experience; potential cost headwind if utilization is higher than expected, but CNC has embedded this in its 2026 Medicare bids.
• Analyst / Sector Sentiment Shift (July 13, 2026): Wells Fargo upgraded Humana (HUM) to Overweight on July 13, citing moderating Medicare Advantage cost trends. An analyst noted that over the past month, evidence suggests cost trends are coming down "potentially in an unprecedented way," and predicted a rotation toward managed care and away from hospitals. Implication: Positive sector tailwind for CNC; confirms the managed care recovery thesis that has driven CNC’s stock higher since Q1 earnings.

8. Insider Transaction Activity

Key Takeaway: The only insider transaction since the Q1 2026 earnings date is a discretionary open-market sale by Director Kenneth Burdick on June 10, 2026 — a meaningful sale of 80,000 shares (~$5.2M at prevailing prices) with no 10b5-1 plan. This is worth flagging given its size and discretionary nature, though director sales are less informative than C-suite transactions. No open-market buys have been filed since Q1 earnings, and no 10b5-1 plan initiations have been disclosed.

Source: SEC Form 4 Filings Database. Transaction date (June 10, 2026) reflects when the trade was executed; filing date (June 11, 2026) reflects when it was disclosed to the SEC. The sale occurred approximately 6 weeks after the Q1 2026 earnings beat and guidance raise, when the stock was trading near $65. The discretionary nature of the sale (no 10b5-1 plan) is worth noting, but director sales are generally less informative than C-suite transactions and may reflect personal liquidity needs. No C-suite open-market sales or buys have been filed since Q1 earnings. The absence of insider buying despite the stock’s significant recovery from its 2025 lows is neutral — management may be in a blackout period ahead of the Q2 print.

Contrast with ELV: ELV CEO Gail Boudreaux purchased ~$1M of ELV stock on July 17, 2026 following the post-earnings selloff — a strong insider confidence signal at a peer. No comparable buy signal exists for CNC insiders at this time.

Appendix: Key Data Sources & Citations

• Visible Alpha Consensus and Actuals Data — All KPI consensus estimates, actuals, and revision history. Source: https://insights.visiblealpha.com/mex/CNC/NMV/IS and https://insights.visiblealpha.com/mex/CNC/NMV/MB
• Stock Price Data — CNC, XLV, SPY daily closing prices. Source: Yahoo Finance.
• Insider Transaction Data — SEC Form 4 filings. Burdick sale: https://www.sec.gov/Archives/edgar/data/1071739/000107173926000127/xslF345X06/wk-form4_1781212935.xml
• CNC Q1 2026 Earnings Call Transcript — April 28, 2026. Source: documents/CNC/transcript/earnings/2026Q1/raw_document.txt
• CNC Q1 2026 Earnings Release — April 27, 2026. Source: documents/CNC/Earnings Release/2026Q1/raw_document.pdf
• CNC 8-K — Board Appointment (Lauren Tyler) — Filed June 22, 2026; effective June 19, 2026. Source: documents/CNC/8K/000107173926000132/
• UNH Q2 2026 Earnings Call Transcript — July 16, 2026. Source: documents/UNH/transcript/earnings/2026Q2/raw_document.txt
• ELV Q2 2026 Earnings Call Transcript — July 15, 2026. Source: documents/ELV/transcript/earnings/2026Q2/raw_document.txt
• MOH Q2 2026 Earnings Call Transcript — July 22–23, 2026. Source: documents/MOH/transcript/earnings/2026Q2/raw_document.txt
• HCA Q2 2026 Pre-Announcement 8-K — July 14, 2026. Source: https://www.sec.gov/Archives/edgar/data/860730/000119312526302539/hca-20260714.htm
• News Digest / Daily News — Various healthcare sector news items, July 2026. Source: Implied News Aggregation.